JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 163 filers reported holding JUNO THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 0.51 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $29,270,000 | +19.4% | 640,352 | +17.2% | 0.01% | +11.1% |
| Q3 2017 | $24,516,000 | -38.2% | 546,504 | -58.8% | 0.01% | -43.8% |
| Q2 2017 | $39,666,000 | +13.2% | 1,327,073 | -15.9% | 0.02% | +14.3% |
| Q1 2017 | $35,034,000 | +150.4% | 1,578,842 | +112.7% | 0.01% | +133.3% |
| Q4 2016 | $13,993,000 | -25.7% | 742,341 | +12.9% | 0.01% | -33.3% |
| Q3 2016 | $18,840,000 | -15.5% | 657,282 | +13.3% | 0.01% | -18.2% |
| Q2 2016 | $22,297,000 | +12.6% | 580,053 | +11.6% | 0.01% | +10.0% |
| Q1 2016 | $19,800,000 | -3.9% | 519,825 | +10.9% | 0.01% | 0.0% |
| Q4 2015 | $20,604,000 | +97.1% | 468,600 | +82.4% | 0.01% | +100.0% |
| Q3 2015 | $10,454,000 | +1235.1% | 256,921 | +1612.8% | 0.01% | – |
| Q4 2014 | $783,000 | – | 15,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |